Myology research highlights
RSS feedAltered gut microbiota in Myasthenia gravis
Myasthenia gravis (MG) is an autoimmune-mediated disorder, the etiology of which involves both environmental factors and genetics. While the exact factors responsible for predisposition to MG remain elusive, it is hypothesized that gut microbiota play a critical role in the pathogenesis of MG. This study investigated whether gut microbiota are altered in MG patients by … [Read more]
Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multi-cohort validation
Objective evaluation of disease activity is challenging in patients with juvenile dermatomyositis (JDM) due to lack of biomarkers, but crucial to avoid both under- and overtreatment. Recently, the authors identified two proteins that highly correlate with JDM disease activity (1): galectin-9 and CXCL10. Here, they validate galectin-9 and CXCL10 as biomarkers for disease activity, assess … [Read more]
Muscle MRI in a large cohort of patients with OPMD
Oculopharyngeal muscular dystrophy (OPMD) is a genetic disorder caused by an abnormal expansion of GCN triplets within the PABPN1 gene. Previous descriptions have focused on lower limb muscles in small cohorts of patients with OPMD, but larger imaging studies have not been performed. Previous imaging studies have been too small to be able to correlate … [Read more]
A large multicenter study of pediatric DM1 for evidence-based management
The aim of this study was to genotypically and phenotypically characterize a large pediatric myotonic dystrophy type 1 (DM1) cohort to provide a solid frame of data for future evidence-based health management. Among the 2,697 patients with genetically confirmed DM1 included in the French DM-Scope registry, children were enrolled between January 2010 and February 2016 … [Read more]
SMArtCARE – A platform to collect real-life outcome data of patients with SMA
Survival and quality of life for patients affected by spinal muscular atrophy (SMA) are thought to have improved over the last decade due to changes in care. In addition, targeted treatments for SMA have been developed based on a better understanding of the molecular pathology. In 2016 and 2017, nusinersen was the first drug to … [Read more]
Echographic assessment of diaphragmatic function in DMD from childhood to adulthood
Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic muscle disorder. Respiratory muscle function is classically affected in this disease. Ultrasound recently emerged as a non-invasive tool to assess diaphragm function. However, there are only a few studies using diaphragm ultrasound (US) in DMD. In this study, French clinicians from the Centre for Reference for … [Read more]
Fractures and linear growth in a nationwide cohort of boys with DMD with and without glucocorticoid treatment: results from the UK NorthStar database
Based on studies with relatively small sample size, fragility fractures are commonly reported in glucocorticoid (GC)-treated boys with Duchenne muscular dystrophy (DMD). This study aimed to determine the fracture burden and growth impairment in a large contemporary cohort of boys with DMD in the United Kingdom and in relation to GC regimen. A retrospective review … [Read more]
Amifampridine phosphate (Firdapse) is effective in a confirmatory phase 3 clinical trial in LEMS
To assess tolerability and efficacy of amifampridine phosphate versus placebo for symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), the authors designed a phase 3 randomized, double-blind, placebo-controlled withdrawal trial in 26 adults with LEMS compared efficacy of amifampridine phosphate versus placebo over a 4-day period. The primary endpoints were quantitative myasthenia gravis score (QMG) and … [Read more]
Long-term evaluation of AAV-CRISPR genome editing for DMD
Duchenne muscular dystrophy (DMD) is a monogenic disorder and a candidate for therapeutic genome editing. There have been several recent reports of genome editing in preclinical models of DMD, however, the long-term persistence and safety of these genome editing approaches have not been addressed. Here, researchers show that genome editing and dystrophin protein restoration is … [Read more]
Is early detection of late-onset Pompe disease a pneumologist’s affair? A lesson from an Italian screening study
Late-onset Pompe disease (LOPD) is a recessive disease caused by α-glucosidase (GAA) deficiency, leading to progressive muscle weakness and/or respiratory failure in children and adults. Respiratory derangement can be the first indication of LOPD, but the diagnosis may be difficult for pneumologists. An Italian team hypothesizes that assessing the GAA activity in suspected patients by … [Read more]